TY - JOUR T1 - Novel monoclonal antibodies showing broad neutralizing activity for SARS-CoV-2 variants including Omicrons BA.5 and BA.2.75 JF - bioRxiv DO - 10.1101/2022.09.02.506305 SP - 2022.09.02.506305 AU - Hanako Ishimaru AU - Mitsuhiro Nishimura AU - Lidya Handayani Tjan AU - Silvia Sutandhio AU - Maria Istiqomah Marini AU - Gema Barlian Effendi AU - Hideki Shigematsu AU - Koji Kato AU - Natsumi Hasegawa AU - Kaito Aoki AU - Yukiya Kurahashi AU - Koichi Furukawa AU - Mai Shinohara AU - Tomoka Nakamura AU - Jun Arii AU - Tatsuya Nagano AU - Sachiko Nakamura AU - Shigeru Sano AU - Sachiyo Iwata AU - Yasuko Mori Y1 - 2022/01/01 UR - http://biorxiv.org/content/early/2022/09/02/2022.09.02.506305.abstract N2 - We identified novel neutralizing monoclonal antibodies against SARS-CoV-2 variants (including Omicron) from individuals received two doses of mRNA vaccination after they had been infected with wildtype. We named them MO1, MO2 and MO3. MO1 shows high neutralizing activity against authentic variants: D614G, Delta, BA.1, BA.1.1, BA.2, and BA.2.75 and BA.5. Our findings confirm that the wildtype-derived vaccination can induce neutralizing antibodies that recognize the epitopes conserved among the SARS-CoV-2 variants (including BA.5 and BA.2.75). The monoclonal antibodies obtained herein could serve as novel prophylaxis and therapeutics against not only current SARS-CoV-2 viruses but also future variants that may arise.Competing Interest StatementThe authors have declared no competing interest. ER -